The taxane limbo: how low can we go?

J Natl Cancer Inst. 2008 Jun 4;100(11):761-3. doi: 10.1093/jnci/djn155. Epub 2008 May 27.
No abstract available

Publication types

  • Editorial
  • Review
  • Comment

MeSH terms

  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / analysis
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Clinical Trials, Phase III as Topic
  • Docetaxel
  • Drug Administration Schedule
  • Female
  • Humans
  • Infusions, Intravenous
  • Meta-Analysis as Topic
  • Neoplasm Staging
  • Paclitaxel / administration & dosage
  • Paclitaxel / therapeutic use*
  • Predictive Value of Tests
  • Prognosis
  • Receptor, ErbB-2 / analysis
  • Retrospective Studies
  • Taxoids / therapeutic use

Substances

  • Antineoplastic Agents, Phytogenic
  • Biomarkers, Tumor
  • Taxoids
  • Docetaxel
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Paclitaxel